The era of genomic medicine has allowed acute myeloid leukemia (AML) researchers to
improve disease characterization, optimize risk-stratification systems, and develop new …

Fms-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid
leukemia (AML). Modern targeting of FLT3 with inhibitors has improved clinical outcomes …

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or
refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed …

Recent advances in FLT3 and IDH targeted inhibition have improved response rates and
overall survival in patients with mutations affecting these respective proteins. Despite this …

The traditionally dismal outcome of acute myeloid leukemia (AML) patients carrying the FMS-
related tyrosine kinase 3 (FLT3) mutations has been mitigated by the recent introduction of …

The treatment of acute myeloid leukemia (AML) has historically relied on cytotoxic
chemotherapy, but modern understanding of AML biology has paved the way for new …

The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI
sensitivity switch to quizartinib - PMC Skip to main content Here's how you know Official …

Mutations in the WT1 transcription factor (WT1) gene are found in~ 5% to 12% of adults with
acute myeloid leukemia (AML) and are generally associated with a poor prognosis. 1-8 …

Leukemia is a malignant tumor with high heterogeneity and a complex evolutionary process.
It is difficult to resolve the heterogeneity and clonal evolution of leukemia cells by applying …

Background Acute myeloid leukemia (AML) is a complex disease with diverse mutations,
including prevalent mutations in the FMS-like receptor tyrosine kinase 3 (FLT3) gene that …